Hoffmann-La Roche's TAT antagonist
Executive Summary
Anti-HIV drug will be developed by the company on its own "after an intensive search for a licensing partner," Roche reports Dec. 19. The firm notes that "there was a great deal of interest" in licensing Ro 24-7429 but felt the TAT antagonist could benefit from Roche's experience with Hivid (ddC). Recent reports of disappointing results with reverse transcriptase inhibitors ("The Pink Sheet" Dec. 2, T&G-7), Roche said, also contributed to its decision to "refocus its efforts on the TAT antagonist." To date, Ro 24-7429 has been studied in two small pilot trials. Roche hopes to begin Phase II efficacy studies in "early 1992".
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth